Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO ANNUAL REPORT
FOR THE EIGHTEEN MONTHS ENDED 31 DECEMBER 2019
Reference is made to the annual report of China Medical & HealthCare Group Limited (the "Company", together with its subsidiaries, collectively the "Group") for the eighteen months ended 31 December 2019 (the "2018/2019 Annual Report"). Capitalised terms used herein shall have the same meanings as those defined in the 2018/2019 Annual Report unless the context requires otherwise.
In addition to the information provided in the 2018/2019 Annual Report, the board of directors (the "Board") of the Company would like to provide further information and breakdown in relation to the other gains and losses, and other income of the Group for the eighteen months ended 31 December 2019, together with the comparative figures for the corresponding financial year in 2018 (twelve months ended
30 June 2018):
1.7.2018 | 1.7.2017 | |
to | to | |
31.12.2019 | 30.6.2018 | |
HK$'000 | HK$'000 | |
Gain (loss) in fair value of investments held for trading | 15,078 | (8,716) |
(Loss) gain in fair value of derivative financial instruments | (4) | 4,244 |
Fair value changes on investment properties | 18,245 | (1,609) |
Net foreign exchange (loss) gain | (11,303) | 12,307 |
Impairment loss under expected credit loss model | (5,062) | - |
Net gain (loss) on disposal of property, plant and equipment | 27 | (1,128) |
Government subsidies | 4,468 | - |
Interest income from: | ||
- Debt instruments at fair value through profit or loss | 1,528 | - |
- Available-for-sale debt instruments | - | 886 |
- Bank deposits | 7,536 | 5,084 | |
Impairment loss recognised on available-for-sale investments | - | (383) | |
Net loss in promissory notes receivable | - | (6,500) | |
Early settlement discount of consideration payable | 1,500 | - | |
Sale of vision-aid products | 3,810 | 819 | |
Clinical training services | 3,087 | 2,322 | |
Subcontracting fees from car parking spaces and canteen | 1,179 | 624 | |
Leasing fees from shopping and other areas of the hospitals | 820 | 306 | |
Forfeiture of customers' deposits | 997 | 369 | |
Other sundry income | 9,163 | 14,264 | |
51,069 | 22,889 |
The additional information set out above does not affect other information contained in the 2018/2019 Annual Report.
By Order of the Board
China Medical & HealthCare Group Limited
Zhou Liye
Chairman
Hong Kong, 31 July 2020
As at the date of this announcement, the Board comprises:
Executive Directors
Ms. Chong Sok Un (Deputy Chairman), Mr. Kong Muk Yin, Mr. Guo Meibao and Mr. Zhou Haiying
Non-Executive Directors
Mr. Zhou Liye (Chairman), Dato' Wong Peng Chong and Mr. Zheng Zhen
Independent Non-Executive Directors
Mr. Zhang Jian, Dr. Xia Xiaoning, Dr. Wong Wing Kuen, Albert and Ms. Yang Lai Sum, Lisa
Attachments
- Original document
- Permalink
Disclaimer
China Medical & HealthCare Group Ltd. published this content on 31 July 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 July 2020 11:01:01 UTC